CD130/gp130 CRISPR Activation Plasmid (h): sc-400301-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CD130/gp130 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- CD130/gp130 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by CD130/gp130 CRISPR Activation Plasmid (h) and CD130/gp130 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the IL6ST transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CD130/gp130 Antibody (E-8): sc-376280
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD130/gp130 CRISPR Activation Plasmid (h) | sc-400301-ACT | 20 µg | $397.00 | |||
CD130/gp130 CRISPR Activation Plasmid (h2) | sc-400301-ACT-2 | 20 µg | $397.00 |
IL6ST encodes CD130/gp130, a ubiquitously expressed signal-transducing co-receptor shared by the IL-6 family of cytokines, including IL6, IL11, LIF, OSM, CNTF, and CT-1. Upon ligand engagement with partner receptor subunits, gp130 activates JAK/STAT3 and STAT1 signaling and interfaces with MAPK/ERK and PI3K/AKT pathways to regulate cell survival, proliferation, differentiation, acute-phase responses, and immune homeostasis. Dysregulated gp130-dependent signaling is implicated in chronic inflammation and autoimmunity, tumor-promoting microenvironmental signaling, and aberrant hematopoietic and stromal cell programs, making IL6ST a key node for pathway dissection in human cell models.
CD130/gp130 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous IL6ST expression without altering the underlying DNA sequence.
CD130/gp130 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the IL6ST locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the IL6ST transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous CD130/gp130 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native IL6ST locus and enabling the study of CD130/gp130-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of CD130/gp130 pathway restoration in tumor cells with silenced or reduced IL6ST expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.